

Heiko Schoder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4870980/publications.pdf>

Version: 2024-02-01

166
papers

10,818
citations

34076

52
h-index

33869

99
g-index

175
all docs

175
docs citations

175
times ranked

11864
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. <i>Science Translational Medicine</i> , 2014, 6, 260ra149.	5.8	589
2	Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	3.4	493
3	Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 4643-4651.	0.8	462
4	Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image Fusion. <i>Radiology</i> , 2004, 231, 65-72.	3.6	372
5	Brown adipose tissue is associated with cardiometabolic health. <i>Nature Medicine</i> , 2021, 27, 58-65.	15.2	332
6	Positron emission tomography for prostate, bladder, and renal cancer. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 274-292.	2.5	312
7	Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1896-1903.	0.8	293
8	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	0.8	266
9	Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 1665-1670.	0.6	258
10	Effect of respiratory gating on quantifying PET images of lung cancer. <i>Journal of Nuclear Medicine</i> , 2002, 43, 876-81.	2.8	253
11	Clinical Utility of ¹⁸ F-FDG PET/CT in Assessing the Neck After Concurrent Chemoradiotherapy for Locoregional Advanced Head and Neck Cancer. <i>Journal of Nuclear Medicine</i> , 2008, 49, 532-540.	2.8	247
12	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	0.8	239
13	Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1789-96.	2.8	235
14	2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2005, 11, 4761-4769.	3.2	210
15	18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged NO by clinical examination and CT/MRI. <i>Journal of Nuclear Medicine</i> , 2006, 47, 755-62.	2.8	183
16	PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2009, 50, 74S-88S.	2.8	172
17	Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3973-3978.	0.8	165
18	Positron emission imaging of head and neck cancer, including thyroid carcinoma. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 180-197.	2.5	164

#	ARTICLE	IF	CITATIONS
19	Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211. <i>Medical Physics</i> , 2017, 44, e1-e42.	1.6	162
20	¹⁸ F-FDG PET/CT Metabolic Tumor Volume and Total Lesion Glycolysis Predict Outcome in Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1506-1513.	2.8	161
21	Diagnostic Accuracy of ¹⁸ F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels. <i>Journal of Nuclear Medicine</i> , 2007, 48, 501-507.	2.8	142
22	Imaging for Staging and Response Assessment in Lymphoma. <i>Radiology</i> , 2015, 276, 323-338.	3.6	139
23	PET/CT: a new imaging technology in nuclear medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1419-1437.	3.3	133
24	Prognostic Value of Baseline [¹⁸ F] Fluorodeoxyglucose Positron Emission Tomography and ^{99m} Tc-MDP Bone Scan in Progressing Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 6093-6099.	3.2	130
25	Prospective Trial Incorporating Pre-/Mid-Treatment [¹⁸ F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 101-108.	0.4	126
26	¹⁸ F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 335-341.	2.8	123
27	A prospective evaluation of the utility of ¹⁸ F-fluoro-deoxyglucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. <i>Cancer</i> , 2012, 118, 5481-5488.	2.0	122
28	Radiation dosimetry of ¹⁸ F-FDG PET/CT: incorporating exam-specific parameters in dose estimates. <i>BMC Medical Imaging</i> , 2016, 16, 41.	1.4	122
29	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 9-17.	0.4	121
30	Hybrid Imaging (SPECT/CT and PET/CT): Improving Therapeutic Decisions. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 308-340.	2.5	118
31	<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019, 9, 199-209.	7.7	115
32	Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 2196-2203.	0.6	111
33	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 742-751.	3.0	98
34	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	0.8	97
35	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹ Zr-Trastuzumab in Patients with Esophagogastric Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 161-166.	2.8	96
36	Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 217.	3.4	93

#	ARTICLE	IF	CITATIONS
37	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. <i>Blood</i> , 2018, 132, 1013-1021.	0.6	90
38	Deep-Inspiration Breath-Hold PET/CT: Clinical Findings with a New Technique for Detection and Characterization of Thoracic Lesions. <i>Journal of Nuclear Medicine</i> , 2007, 48, 712-719.	2.8	87
39	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1238-1246.	0.6	86
40	The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. <i>Current Opinion in Urology</i> , 2008, 18, 87-97.	0.9	83
41	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. <i>Blood</i> , 2016, 128, 469-469.	0.6	79
42	Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 930-939.	3.3	75
43	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Neuro-Oncology</i> , 2021, 23, 1056-1071.	0.6	68
44	Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 672-679.	0.4	68
45	Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. <i>Journal of Nuclear Medicine</i> , 2020, 61, 626-629.	2.8	65
46	A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. <i>Blood</i> , 2021, 138, 2828-2837.	0.6	65
47	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020, 135, 2224-2234.	0.6	62
48	Predicting Outcome in Patients with Rhabdomyosarcoma: Role of [18F]Fluorodeoxyglucose Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1136-1142.	0.4	61
49	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. <i>Blood</i> , 2016, 128, 1458-1464.	0.6	61
50	Target Volume Delineation in Oropharyngeal Cancer: Impact of PET, MRI, and Physical Examination. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 220-227.	0.4	60
51	Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. <i>Journal of Nuclear Medicine</i> , 2004, 45, 559-66.	2.8	60
52	Molecular imaging of prostate cancer. <i>Current Opinion in Urology</i> , 2012, 22, 320-327.	0.9	56
53	Metabolic Tumor Volume in Lymphoma: Hype or Hope?. <i>Journal of Clinical Oncology</i> , 2016, 34, 3591-3594.	0.8	56
54	Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features. <i>Radiotherapy and Oncology</i> , 2018, 127, 36-42.	0.3	55

#	ARTICLE	IF	CITATIONS
55	Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2760-2769.	3.3	55
56	Clinical Significance of Unexplained Abnormal Focal FDG Uptake in the Abdomen During Whole-Body PET. <i>American Journal of Roentgenology</i> , 2004, 183, 1143-1147.	1.0	54
57	Interim [¹⁸ F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. <i>Leukemia and Lymphoma</i> , 2012, 53, 2143-2150.	0.6	54
58	Advances in oncologic imaging. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 364-393.	157.7	53
59	Initial Results with 11C-Acetate Positron Emission Tomography/Computed Tomography (PET/CT) in the Staging of Urinary Bladder Cancer. <i>Molecular Imaging and Biology</i> , 2012, 14, 245-251.	1.3	51
60	Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics. <i>Physics in Medicine and Biology</i> , 2017, 62, 5327-5343.	1.6	51
61	Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. <i>Lancet Oncology</i> , The, 2020, 21, e431-e443.	5.1	51
62	Brown adipose tissue is associated with healthier body fat distribution and metabolic benefits independent of regional adiposity. <i>Cell Reports Medicine</i> , 2021, 2, 100332.	3.3	51
63	Noncontrast Perfusion Single-Photon Emission CT/CT Scanning. <i>Chest</i> , 2014, 145, 1079-1088.	0.4	50
64	¹⁸ F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1052-1057.	2.8	50
65	Screening for cancer with PET and PET/CT: potential and limitations. <i>Journal of Nuclear Medicine</i> , 2007, 48 Suppl 1, 4S-18S.	2.8	49
66	Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1727-1732.	2.8	46
67	PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. <i>Journal of Nuclear Medicine</i> , 2004, 45 Suppl 1, 72S-81S.	2.8	46
68	Prospective Study of 3-Deoxy- ¹⁸ F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 728-734.	2.8	41
69	The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. <i>Gynecologic Oncology</i> , 2013, 129, 586-592.	0.6	40
70	PET Imaging for Response Assessment in Lymphoma: Potential and Limitations. <i>Radiologic Clinics of North America</i> , 2008, 46, 225-241.	0.9	39
71	Evaluation of Different Methods of 18F-FDG-PET Target Volume Delineation in the Radiotherapy of Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 439-445.	0.6	38
72	Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3110-3116.	3.2	36

#	ARTICLE	IF	CITATIONS
73	Phase II trial of bevacizumab+cetuximab+cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E566-70.	0.9	35
74	The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [18F] fluorodeoxyglucose positron emission tomography scan. <i>Oral Oncology</i> , 2014, 50, 802-808.	0.8	34
75	Advances in positron emission tomography applications for urologic cancers. <i>Current Opinion in Urology</i> , 2008, 18, 65-70.	0.9	33
76	Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1682-1691.	3.3	33
77	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	0.8	32
78	Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement. <i>American Journal of Roentgenology</i> , 2017, 208, 849-853.	1.0	31
79	Multiparametric Imaging of Tumor Hypoxia and Perfusion with ¹⁸ F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1072-1080.	2.8	31
80	Novel Approaches to Thyroid Cancer Treatment and Response Assessment. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 109-118.	2.5	30
81	Molecular targeting of the lymphovascular system for imaging and therapy. <i>Cancer and Metastasis Reviews</i> , 2006, 25, 185-201.	2.7	29
82	Clinical utility of perfusion (Q)-single-photon emission computed tomography (SPECT)/CT for diagnosing pulmonary embolus (PE) in COVID-19 patients with a moderate to high pre-test probability of PE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 794-799.	3.3	29
83	Feasibility of In Situ, High-Resolution Correlation of Tracer Uptake with Histopathology by Quantitative Autoradiography of Biopsy Specimens Obtained Under ¹⁸ F-FDG PET/CT Guidance. <i>Journal of Nuclear Medicine</i> , 2015, 56, 538-544.	2.8	28
84	MRI and PET/MRI in hematologic malignancies. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1325-1335.	1.9	28
85	CT in PET/CT: essential features of interpretation. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1249-51.	2.8	27
86	Positron Emission Tomography/Computerized Tomography Functional Imaging of Esophageal and Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2004, 10, 243-250.	1.0	26
87	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2642-2651.	3.3	26
88	Fundamentals of Molecular Imaging: Rationale and Applications With Relevance for Radiation Oncology. <i>Seminars in Nuclear Medicine</i> , 2008, 38, 119-128.	2.5	25
89	Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy. <i>Cancer</i> , 2015, 121, 1985-1992.	2.0	25
90	Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer. <i>EJNMMI Research</i> , 2016, 6, 79.	1.1	25

#	ARTICLE	IF	CITATIONS
91	Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL. <i>Blood</i> , 2006, 108, 532-532.	0.6	25
92	[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients. <i>Cancers</i> , 2020, 12, 1138.	1.7	24
93	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1386-1406.	3.3	24
94	Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. <i>Radiology</i> , 2015, 277, 518-526.	3.6	23
95	EANM/SNMMI practice guideline for [18F]FDG PET/CT external beam radiotherapy treatment planning in uterine cervical cancer v1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1188-1199.	3.3	23
96	Pharmacokinetic Analysis of Dynamic ¹⁸ F-Fluoromisonidazole PET Data in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 911-919.	2.8	22
97	Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma. <i>Blood Advances</i> , 2018, 2, 649-655.	2.5	22
98	Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. <i>Blood Advances</i> , 2020, 4, 1812-1823.	2.5	22
99	A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3618-3630.	3.3	21
100	Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 485-501.	2.5	21
101	The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in ¹⁸ F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1424-1430.	2.8	20
102	ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma. <i>Cancer</i> , 2013, 119, 1203-1209.	2.0	19
103	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. <i>Radiotherapy and Oncology</i> , 2020, 153, 97-105.	0.3	19
104	A Prospective Study of 18FDG-PET With CT Coregistration for Radiation Treatment Planning of Lymphomas and Other Hematologic Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 376-383.	0.4	18
105	¹¹ C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series. <i>Journal of Nuclear Medicine</i> , 2020, 61, 827-833.	2.8	18
106	Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1285-93.	0.9	17
107	Functional imaging using radiomic features in assessment of lymphoma. <i>Methods</i> , 2021, 188, 105-111.	1.9	17
108	Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 16.	0.6	17

#	ARTICLE	IF	CITATIONS
109	The current status of positron-emission tomography scanning in the evaluation and follow-up of patients with head and neck cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2006, 14, 73-81.	0.8	16
110	Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times. <i>Journal of Nuclear Medicine</i> , 2016, 57, 334-341.	2.8	16
111	Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2021, 11, 663.	1.3	16
112	Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. <i>American Journal of Hematology</i> , 2021, 96, 1211-1222.	2.0	16
113	Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. <i>Journal of Clinical Oncology</i> , 2022, 40, 1500-1505.	0.8	16
114	Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1658-1665.	2.9	15
115	Current Status of the Role of PET Imaging in Diffuse Large B-Cell Lymphoma. <i>Seminars in Hematology</i> , 2015, 52, 138-142.	1.8	15
116	18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1446-1457.	3.3	13
117	Overcoming the COVID-19 Crisis and Planning for the Future. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1096-1101.	2.8	13
118	Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review. <i>Annals of Lymphoma</i> , 2021, 5, 15-15.	4.5	13
119	Phase I/II Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. <i>Clinical Cancer Research</i> , 2022, 28, 45-56.	3.2	13
120	Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 506-514.	0.6	12
121	Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging. <i>Nuclear Medicine and Biology</i> , 2020, 84-85, 80-87.	0.3	12
122	Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma. <i>Blood</i> , 2008, 112, 264-264.	0.6	12
123	¹¹ C-Choline Pharmacokinetics in Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1672-1678.	2.8	11
124	Imaging of CAR T-Cells in Cancer Patients: Paving the Way to Treatment Monitoring and Outcome Prediction. <i>Journal of Nuclear Medicine</i> , 2019, 60, 879-881.	2.8	11
125	Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. <i>Annals of Surgery</i> , 2018, 267, 898-904.	2.1	9
126	The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1833-1841.	0.6	9

#	ARTICLE	IF	CITATIONS
127	Practice and prospects for PET/CT guided interventions. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 20-31.	0.4	9
128	A pilot study of ¹³ N-ammonia cardiac PET imaging to assess subacute cardiotoxicity following adjuvant intensity-modulated radiotherapy for locally advanced breast cancer. Clinical Imaging, 2020, 68, 283-290.	0.8	8
129	Prognostic value of [¹⁸ F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3940-3950.	3.3	8
130	FDG PET/CT imaging features and clinical utility in COVID-19. Clinical Imaging, 2021, 80, 262-267.	0.8	8
131	Adnexal mass secondary to extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with associated amyloid deposition. BMJ Case Reports, 2014, 2014, bcr2014206699-bcr2014206699.	0.2	8
132	Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage – Case Report. Frontiers in Oncology, 2017, 7, 284.	1.3	7
133	A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. Breast Cancer Research and Treatment, 2021, 188, 415-425.	1.1	7
134	Diagnostic and Prognostic Utility of ¹⁸ F-FDG PET/CT in Recurrent Salivary Gland Cancers. American Journal of Roentgenology, 2021, 216, 1344-1356.	1.0	6
135	Impact of ¹⁸ F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis. European Journal of Cancer, 2021, 159, 60-77.	1.3	6
136	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Blood, 2020, 136, 17-18.	0.6	5
137	Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer. Cancer, 2019, 125, 2984-2990.	2.0	4
138	The Path to the Future: Education of Nuclear Medicine Therapeutic Specialists as Responsible Physicians. Journal of Nuclear Medicine, 2019, 60, 1663-1664.	2.8	4
139	[⁸⁹ Zr]-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 783-785.	3.3	4
140	Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma. Blood, 2019, 134, 1555-1555.	0.6	4
141	Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[¹⁸ F]FDG-PET/CT external beam radiation treatment planning in lung cancer. Radiotherapy and Oncology, 2022, 168, 37-39.	0.3	4
142	Treatment response and clinical outcomes of well differentiated high grade neuroendocrine tumors to lutetium-177 DOTATATE. Neuroendocrinology, 0, , .	1.2	4
143	A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma. Tumor Microenvironment and Therapy, 2015, 2, 14-18.	1.2	3
144	Application of Community Detection Algorithm to Investigate the Correlation between Imaging Biomarkers of Tumor Metabolism, Hypoxia, Cellularity, and Perfusion for Precision Radiotherapy in Head and Neck Squamous Cell Carcinomas. Cancers, 2021, 13, 3908.	1.7	3

#	ARTICLE	IF	CITATIONS
145	Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404. <i>Blood</i> , 2008, 112, 372-372.	0.6	3
146	Interim PET Evaluation By Deauville Criteria Is an Effective Risk Stratification Tool in PTCL. <i>Blood</i> , 2016, 128, 186-186.	0.6	3
147	Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance). <i>Blood</i> , 2016, 128, 2953-2953.	0.6	3
148	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2177-2183.	0.6	2
149	Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588. <i>Blood</i> , 2016, 128, 4198-4198.	0.6	2
150	Reply to A. HÃ¼ttmann et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e490-e491.	0.8	1
151	Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer. <i>World Journal of Radiology</i> , 2017, 9, 134.	0.5	1
152	An International Survey of PET/CT Clinical Reporting. <i>Journal of Nuclear Medicine</i> , 2019, 60, 478-479.	2.8	1
153	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. <i>Leukemia and Lymphoma</i> , 2020, 61, 2442-2447.	0.6	1
154	Urachal remnant metastasis detected on [68Ga] PSMA-11 PET/CT in an asymptomatic prostate cancer patient with biochemical recurrence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3003-3004.	3.3	1
155	Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL). <i>Blood</i> , 2021, 138, 2447-2447.	0.6	1
156	Metabolic Tumor Volume and Total Lesion Glycolysis Can Predict Response to Very Low Dose Radiotherapy (4 Gy) in Indolent B-Cell Lymphomas. <i>Blood</i> , 2021, 138, 3518-3518.	0.6	1
157	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.	2.8	1
158	Head, neck, and thyroid. , 0, , 103-127.		0
159	To scan or not to scan? The value of radiologic surveillance in early-stage Hodgkin lymphoma. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 181-183.	0.7	0
160	Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2331-2334.	1.3	0
161	Diagnostic Applications of Nuclear Medicine: Head and Neck Cancer. , 2016, , 1-37.		0
162	Teaching Cases in Nuclear Oncology: Head and Neck Cancer. , 2016, , 1-16.		0

#	ARTICLE	IF	CITATIONS
163	Teaching Cases in Nuclear Oncology: Head and Neck Cancer. , 2017, , 1569-1583.		0
164	Diagnostic Applications of Nuclear Medicine: Head and Neck Cancer. , 2017, , 507-543.		0
165	Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]. Blood, 2020, 136, 50-50.	0.6	0
166	PET imaging in renal and bladder cancers. , 2022, , .		0